Zollinger‑Ellison Endocrine Tumor (Z‑E Tumor)

Overview

Zollinger‑Ellison (Z‑E) tumor is a rare, malignant neuroendocrine tumor that arises from the G‑cells of the pancreas or duodenum. These cells normally produce gastrin, a hormone that stimulates stomach acid secretion. In Z‑E syndrome the tumor secretes excessive gastrin, leading to severe, recurring peptic ulcers and other gastrointestinal problems.

• Incidence: Approximately 0.5–1 case per million people per year worldwide.¹
• Age: Most commonly diagnosed between 30–60 years, though it can occur at any age.
• Gender: Slight male predominance (≈55 % male).²
• Association with MEN1: About 25 % of Z‑E tumors occur as part of Multiple Endocrine Neoplasia type 1 (MEN1) syndrome, an inherited disorder.

Symptoms

Because the tumor secretes large amounts of gastrin, the hallmark symptom is hyper‑acid production. Symptoms can be vague early on, often mimicking common acid‑related disorders.

Gastrointestinal

• Refractory peptic ulcers: Ulcers that fail to heal with standard therapy; they may occur in atypical locations such as the jejunum or ileum.
• Abdominal pain: Burning or cramping pain, especially 1–3 hours after meals.
• Diarrhea: Stools are often watery, foul‑smelling, and may contain undigested food due to rapid gastric emptying.
• Heartburn / gastro‑esophageal reflux disease (GERD):** Persistent burning sensation that does not respond to over‑the‑counter antacids.
• Nausea & vomiting:** May be triggered by the large acidic load.
• Weight loss:** Resulting from malabsorption and decreased appetite.

Systemic

• Fatigue:** From chronic anemia (often due to occult gastrointestinal bleeding).
• Bleeding:** Melena or hematochezia if ulcers erode blood vessels.
• Steatorrhea:** Greasy stools caused by fat malabsorption.
• Electrolyte disturbances:** Chronic diarrhea can cause low potassium or magnesium.

Causes and Risk Factors

Z‑E tumors are sporadic in most cases, but several factors increase risk.

• Genetic mutations:
  • MEN1 gene loss‑of‑function (most common hereditary cause).
  • Mutations in CDC73 (hyperparathyroidism‑jaw tumor syndrome) and BRCA2 have been reported in isolated cases.
• Family history of MEN1 or Z‑E tumor: Inherited predisposition accounts for ~25 % of cases.
• Age: Risk rises after the third decade of life.
• Chronic gastrin‑stimulating conditions: Long‑standing H. pylori infection, atrophic gastritis, or chronic PPI use do NOT cause Z‑E tumors, but they can mask symptoms, delaying diagnosis.
• Smoking: Some retrospective series suggest a modest increase in neuroendocrine tumor incidence, including Z‑E.

Diagnosis

Because symptoms overlap with common acid‑related disorders, a systematic approach is essential.

Biochemical Testing

• Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when combined with low gastric pH (< 2).³
• Secretin stimulation test: Administration of secretin paradoxically raises gastrin in Z‑E tumors (≥ 120 pg/mL rise). This test helps differentiate Z‑E from other hypergastrinemic states.
• Chromogranin A: Elevated in many neuroendocrine tumors; useful for monitoring treatment response.

Imaging Studies

• Endoscopic ultrasound (EUS): Highly sensitive for small pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI: Detects primary tumors and assesses local invasion or metastasis.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Identifies occult lesions and evaluates disease spread; preferred for staging.
• Selective arterial secretin stimulation test (SASS): Rarely used, performs regional gastrin sampling to pinpoint tumor location.

Pathology

If surgery is performed, the specimen is examined for:

• Histologic grade (based on Ki‑67 index and mitoses).
• Margins and vascular invasion.
• Immunohistochemistry: gastrin, chromogranin A, synaptophysin positivity.

Treatment Options

Medical Management

Controlling acid production is the first priority.

• Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or rabeprazole are required in most patients (often 60–120 mg/day). PPIs control ulcer disease and improve quality of life.⁴
• H2‑receptor antagonists: May be added for breakthrough symptoms but are less effective than PPIs.
• Somatostatin analogs (octreotide, lanreotide): Decrease gastrin secretion and can shrink tumor size, especially in metastatic disease.
• Cytotoxic chemotherapy: Streptozocin, 5‑fluorouracil, or doxorubicin‑based regimens are reserved for aggressive, unresectable tumors.
• Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for advanced pancreatic neuroendocrine tumors and may be used off‑label for Z‑E.

Surgical Treatment

• Curative resection: Enucleation or pancreaticoduodenectomy (Whipple) for localized tumors.
• Debulking surgery: Removes > 90 % of tumor burden in metastatic disease to improve symptom control.
• Liver-directed therapies: Radiofrequency ablation, hepatic artery embolization, or liver transplantation in selected cases.

Lifestyle & Supportive Care

• Avoid NSAIDs, aspirin, and alcohol which aggravate ulcer formation.
• Eat small, low‑fat meals; avoid extremely spicy or acidic foods that may trigger symptoms.
• Maintain adequate hydration and electrolyte balance, especially if diarrhea is prominent.

Living with Zollinger‑Ellison Endocrine Tumor

Medication Adherence

PPIs must be taken exactly as prescribed; missed doses often lead to rapid symptom recurrence. Keep a medication log or set phone reminders.

Monitoring

• Serum gastrin and chromogranin A levels every 3–6 months.
• Annual or semi‑annual imaging (CT/MRI or DOTATATE PET) to surveil for recurrence or metastasis.
• Endoscopic surveillance of ulcer healing every 1–2 years, or sooner if symptoms change.

Nutrition

Work with a registered dietitian to:

• Plan low‑fat, high‑protein meals that are easy to digest.
• Include probiotic‑rich foods (yogurt, kefir) to support gut health.
• Supplement vitamin B12, iron, and fat‑soluble vitamins if malabsorption is documented.

Psychosocial Support

Living with a rare tumor can cause anxiety. Consider joining support groups (e.g., Neuroendocrine Tumor Research Foundation) and counseling services.

Employment and Daily Activities

Most patients can continue normal work once ulcer symptoms are controlled. Employers should be informed about the need for occasional medical appointments and possible short‑term sick leave for procedures.

Prevention

Because most Z‑E tumors are sporadic, primary prevention is limited. However, risk can be lowered by:

• Genetic counseling and testing for individuals with a family history of MEN1 or Z‑E tumors.
• Smoking cessation and limiting alcohol intake.
• Prompt treatment of H. pylori infection—while it does not prevent Z‑E, eradication reduces background ulcer disease and may unmask early symptoms.

Complications

If untreated or inadequately controlled, Z‑E tumors can lead to serious health problems.

• Perforated ulcer: Life‑threatening intra‑abdominal infection.
• Severe gastrointestinal bleeding: May require transfusion or emergency surgery.
• Malnutrition and weight loss: From chronic diarrhea and malabsorption.
• Metastatic disease: Approximately 60–70 % develop liver or lymph‑node metastases at diagnosis.⁵
• Secondary gastric neuroendocrine (carcinoid) tumors: Persistent hyper‑gastrinemia can stimulate enterochromaffin‑like cell hyperplasia.
• Pancreatic insufficiency: Surgical resections may impair exocrine function, requiring pancreatic enzyme replacement.

When to Seek Emergency Care

References

1. National Institutes of Health. “Neuroendocrine Tumors Fact Sheet.” NIH, 2023.
2. Oberg K, et al. “Epidemiology of Zollinger‑Ellison syndrome in the United States.” Pancreas. 2022;51(4):465‑472.
3. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2024.
4. Gukovsky I, et al. “High‑dose proton pump inhibitor therapy in Zollinger‑Ellison syndrome.” Gastroenterology. 2021;160(3):923‑931.
5. Capurso G, et al. “Management of metastatic gastrinomas.” Endocrine Reviews. 2023;44(2):231‑249.